Study based at the Icahn School of Medicine at Mount Sinai and other centers finds new system has safety, efficacy benefits for people with type 1 diabetes
La investigación sobre la anatomía patológica de la lesión pulmonar asociada al uso del cigarrillo electrónico está en etapas iniciales, pero, de acuerdo con un estudio llevado adelante por Mayo Clinic que se publicó en el The New England Journal of Medicine, las lesiones pulmonares por uso del cigarrillo electrónico posiblemente son producto de la intoxicación directa o del daño en los tejidos provocado por los vapores químicos nocivos.
Um estudo liderado pela Mayo Clinic publicado no The New England Journal of Medicine descobriu que as lesões pulmonares causadas pelo uso de cigarros eletrônicos provavelmente são causadas por toxicidade direta ou dano tecidual causado por vapores químicos nocivos.
Eine von der Mayo Clinic geleitete Studie, die in The New England Journal of Medicine veröffentlicht wurde, hat ergeben, dass Lungenverletzungen durch Vaping höchstwahrscheinlich von der direkten Toxizität oder Gewebeverletzungen durch giftige chemische Dämpfe verursacht.
Une étude menée par la Mayo Clinic et publiée dans The New England Journal of Medicine révèle que les lésions pulmonaires dues au vapotage sont très probablement causées par une toxicité directe ou des lésions tissulaires dues à des vapeurs chimiques nocives.
Research into the pathology of vaping-associated lung injury is in its early stages, but a Mayo Clinic study published in The New England Journal of Medicine finds that lung injuries from vaping most likely are caused by direct toxicity or tissue damage from noxious chemical fumes.
لا يزال البحث في علم أمراض إصابات الرئة المصاحبة لتدخين السجائر الإلكترونية في مراحله الأولية، ولكن دراسة أجرتها Mayo Clinic ونشرتها في المجلة الطبية The New England Journal of Medicine وجدت أن إصابات الرئة بسبب تدخين السجائر الإلكترونية غالبًا ما تنتج عن التسمم المباشر أو تلف الأنسجة من جراء الأبخرة الكيميائية الضارة.
A new study of African Americans with poorly controlled asthma, found differences in patients’ responses to commonly used treatments. Contrary to what researchers had expected, almost half of young children in the study responded differently than older children and adults, and than white children in prior studies.
The three-year results from the COAPT trial demonstrated that reducing severe secondary mitral regurgitation (SMR) with the MitraClip device safely improves prognosis in selected heart failure (HF) patients. In addition, those patients that crossed over and received the MitraClip after 24 months showed the same benefits as those who received the device at the beginning of the study. Two-year data were presented at TCT 2018 and published in the New England Journal of Medicine.
Patients with left main coronary artery disease (LMCAD) typically have a poor prognosis due to the large amount of myocardium at risk. Revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) has been shown to prolong survival in patients with left main disease compared with medical therapy alone. Three-year data from the large-scale randomized ECXEL trial found no significant difference in the composite rate of death, stroke or myocardial infarction (MI) between the two treatments, with a reduction in 30-day major adverse events with PCI. These results were first reported at TCT 2016 and published in NEJM.
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.
The trial was conducted on 1,495 patients 50 or older who had been able to walk before having a displaced femoral neck fracture, at 80 centres in the 10 countries of Canada, the U.S., Spain, United Kingdom, Netherlands, Norway, Finland, Australia, New Zealand and South Africa.
Results from international clinical trial ‘TWILIGHT’ could change standard of care for high-risk cases
Secret-shopper-style study of nine Web-based and digital-app vendors of contraception scripts shows their services are overall safe and efficient Analysis also reveals reliable screening by vendors for contraindicated health conditions and medications in line with CDC prescription guidelines Such services may help reduce barriers to contraception and expand access for underserved populations Further improvements needed, particularly in counseling about alternative birth control methods and ensuring patient ability to adhere to prescribed medication
In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures. In a separate study, the investigators reported that ustekinumab is more effective than placebo as an induction and maintenance therapy for UC. The studies were published today in the The New England Journal of Medicine.
Hospitals routinely implement processes aimed at increasing provision of high quality care for patients, such as calling patients to encourage follow-up visits or providing doctors and nurses with alerts in electronic health records to prompt reminders for vaccinations.
A single pill containing low doses of three medications to treat high blood pressure and one to lower cholesterol reduced the estimated risk of cardiovascular disease by 25% in a study published today in the New England Journal of Medicine (NEJM).
Scientists at the Lowy Medical Research Institute (LMRI) have discovered one cause of a progressive, debilitating eye disease called macular telangiectasia type 2 (MacTel). The work, using genetic, clinical and biochemical studies has implications for other retinal eye diseases, as well as peripheral neuropathies.
Paul S. Bernstein, MD, PhD, spent more than a decade working with families at the John A. Moran Eye Center at the University of Utah on the hunt for the first gene known to cause a rare retinal disease known as MacTel.
Unmarried patients with cancer are less likely to get potentially life-saving surgery or radiotherapy than their married counterparts, raising the concern that medical providers may be relying on stereotypes that discount sources of social support other than a current spouse. That's the conclusion reached by the University of Delaware's Joan DelFattore, a professor emerita who combined her personal experience as an unmarried patient with her skills as a researcher to publish a peer-reviewed article in the latest issue of The New England Journal of Medicine.
The new study, a collaboration of 130 hospitals in 31 countries, has shown that opening all the blockages is better than treating only the one blockage causing the heart attack. This led to a 26 per cent reduction in the patient’s risk of dying or having a recurrent heart attack.
Mount Sinai researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies, according to results of a clinical trial published in The New England Journal of Medicine in August.
A new study shows how one state’s surgeons reduced the number of opioids they prescribed to thousands of patients -- without causing patients to feel more pain or less satisfied with their surgical experience.
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
In a perspective article in the New England Journal of Medicine, a group of prominent physician-scientist leaders proposes a plan for increasing the number of physicians who conduct research looking for tomorrow’s breakthroughs and cures. They write, “Revitalizing the physician-scientist pipeline is of critical importance to overcoming current and future health challenges.”
Using advanced technology, scientists at Chan Zuckerberg (CZ) Biohub, Mayo Clinic and UC San Francisco, have discovered an autoimmune disease that appears to affect men with testicular cancer.
A Phase II clinical trial led by MD Anderson found that treatment with the FGFR inhibitor erdafitinib was effective in 40% of patients with metastatic bladder cancers marked by FGFR3 mutations. The trial results led to FDA approval of the drug.
Over eight years, patients covered under a global budget payment model for doctors and hospitals showed slower spending growth and better quality than comparable populations mostly under the traditional fee-for-service model.
A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System.
Nearly 1 in 7 brain-injured patients show early evidence of hidden consciousness—as revealed by EEG analysis—and are more likely to recover, researchers at Columbia have found.
June 19 is World Sickle Cell Awareness Day. Scientists at Cincinnati Children's have recently made three important steps forward in helping people with sickle cell in the U.S. and in sub-Saharan Africa live longer, better lives.
Researchers at Johns Hopkins Medicine, the Murdoch Children’s Research Institute in Australia and seven other medical institutions report that an experimental drug called vosoritide, which interferes with certain proteins that block bone growth, allowed the average annual growth rate to increase in a study of 35 children and teenagers with achondroplasia, a form of dwarfism. The patients’ average boost in height to about 6 centimeters (2.4 inches) per year is close to growth rates among children of average stature, and the side effects of the drug were mostly mild, according to the researchers.
A drug that targets the immune system can delay the onset of type 1 diabetes an average of two years in children and adults at high risk, according to findings from TrialNet’s Teplizumab (anti-CD3) Prevention Study published in the New England Journal of Medicine.
It is common for patients to prefer seeking care from a clinician similar to them — such as of the same gender, ethnicity and culture — who can relate to their experiences and make treatment plans that work better for their lives. To meet these preferences from patients and improve quality of care, a diverse clinician workforce that matches the diversity in the general population is needed. However, when it comes to patients with disabilities, the chance of getting a clinician “like them” is extremely low, which may lead to patients’ reluctance to seek care or follow prescribed interventions and treatments. Meanwhile, without adequate scientists with disabilities bringing perspectives to patient-centered research, the ability to improve care for patients with disabilities is limited.
Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas cancer OLaparib Ongoing) trial.
Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers. This publication accompanies a presentation today that outlines the study results at the American Society for Clinical Oncology (ASCO). Researchers found that treatment with apalutamide significantly improved overall survival, with a 33% reduction in risk of death compared to standard-of-care therapy. Additionally, this study showed apalutamide significantly delayed disease progression and increased the amount of time until a patient has to receive chemotherapy.
Board certified in neurology and vascular neurology, Shadi Yaghi, MD, will oversee the Joint Commission–accredited Comprehensive Stroke Center at NYU Langone Hospital–Brooklyn and director clinical vascular neurology research for NYU Langone Health.
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
At a time when a growing number of men with prostate cancer considered “low risk” are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.
Reversibly paralyzing and heavily sedating hospitalized patients with severe breathing problems do not improve outcomes in most cases, according to a clinical trial conducted at dozens of North American hospitals. The trial settles a long-standing debate in the critical care medicine community.
قلّل دواء إيكوليزوماب "eculizumab"، وهو عبارة عن جسم مضاد اصطناعي يثبّط الاستجابة الالتهابية، بشكل كبير من مخاطر الانتكاس لمرض اضطراب طيف التهاب النخاع والعصب البصري (NMOSD). قد يسبب هذا الاضطراب الالتهابي المناعي الذاتي الذي يُعدّ مرضًا نادرًا لكنه حاد الإصابة بالعمى والشلل والموت. قدّم الباحثون والمتعانون الدوليون لدى Mayo Clinic النتائج التي توصلوا إليها في دراسة عشوائية مزدوجة التعمية باستخدام دواء وهمي، والتي نشرت في المجلة الطبية New England Journal of Medicine . وسيتم تقديم عملهم أيضًا في جلسة منصة العلوم الناشئة، وهي جزء من الاجتماع السنوي الواحد والسبعين للأكاديمية الأمريكية لعلم الأعصاب المنعقد في الفترة ما بين 4 إلى 10 مايو/أيّار في فيلادلفيا.
O medicamento eculizumab, um anticorpo sintético que inibe a resposta inflamatória, reduziu significativamente o risco de recaída do doenças do espectro neuromielite óptica (NMOSD). Esse distúrbio inflamatório autoimune raro, mas grave, pode causar cegueira, paralisia e morte.
The deadly Nipah virus, which is carried by bats and occasionally infects people, is more likely to be transmitted from person to person when the infected patient is older, male and/or has breathing difficulties, according to a study co-led by scientists at the Johns Hopkins Bloomberg School of Public Health.
The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD). Mayo Clinic researchers and international collaborators published their findings in the New England Journal of Medicine.
The American Society of Anesthesiologists (ASA) is pleased with the Centers for Disease Control and Prevention (CDC) article published in the New England Journal of Medicine acknowledging problems with the agency’s Guideline for Prescribing Opioids for Chronic Pain. ASA has been a longtime advocate for the Guideline and was involved in its review and development in 2016.
Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right